Future Science Group
Browse
IMAGE
supplementary figure 1.png (45.33 kB)
IMAGE
supplementary figure 2.png (45.97 kB)
IMAGE
supplementary figure 3.png (51.62 kB)
IMAGE
supplementary figure 4.png (41 kB)
1/0
4 files

Prognostic and clinicopathologicalsignificance of FOXD1 in various cancers: ameta and bioinformation analysis: supplementary figures

Download all (183.92 kB)
figure
posted on 2023-09-07, 15:10 authored by Xiaohan Liu, Shengyun Min, Qin Zhang, Yan Liu, Zhenhong Zou, Nanye Wang, Bin Zhou

Aim: To examine both predictive and clinicopathological importance underlying FOXD1 in malignant

tumors, our study adopts meta-analysis. Methods: We searched from PubMed, Embase, WOS, Wanfang

and CNKI. Stata SE15.1 was used to calculate the risk ratio (HR) as well as relative risk (RR) with 95%

of overall confidence intervals (CIs) to assess FOXD1 and overall survival rate (OS), disease-free survival

rate (FOXD1) as well as clinicopathological parameters. Results: 3808 individuals throughout 17 trials

showed high FOXD1 expression was linked to disadvantaged OS (p < 0.001) and disease-free survival

(p < 0.001) and higher TNM stage (p < 0.001). Conclusion: Elevated FOXD1 had worse predictions and

clinicopathological parameters in most cancers. The GEPIA database findings also support our results.

Funding

This research was financed by the National Natural Science Foundation of China (no. 81860420), the Youth Foundation project of the Jiangxi provincial science and Technology Department (no. 20192BAB215031), and Jiangxi Province Department of Education (GJJ180141).

History

Usage metrics

    Future Science OA

    Categories

    Keywords

    biomarkerscancerFOXD1meta-analysisprognosis

    Licence

    CC BY 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC